Advertisement
AZTA or BIO or TMO
Which Stock Would AI Choose? Azenta, Inc. (AZTA) vs. Bio-Rad Laboratories, Inc. (BIO) vs. Thermo Fisher Scientific Inc. (TMO) Stock Comparison
Key Takeaways
- AZTA has navigated a leadership transition and completed the divestiture of non-core assets, with recent full repayment of a vendor loan strengthening its balance sheet amid ongoing operational focus in life sciences services.
- BIO reported flat year-over-year revenue in its most recent quarter, supported by growth in digital PCR instruments, while implementing restructuring measures to improve margins and address softness in academic research demand.
- TMO delivered 5% organic revenue growth in the second quarter—the strongest pace since 2021—and raised its full-year outlook, bolstered by portfolio optimization including the sale of its microbiology business.
- Relative performance shows TMO maintaining larger scale and broader end-market exposure, while AZTA and BIO exhibit more targeted positioning with varying degrees of recent volatility tied to internal transitions.
- Sector exposure across all three centers on life sciences tools and diagnostics, with differing sensitivities to academic funding, biopharma spending, and recurring revenue streams.
- Market sentiment reflects cautious optimism for larger players with proven execution, contrasted by transition-related considerations for smaller peers.
Introduction
Investors and traders seeking to compare mid- and large-cap life sciences companies often examine AZTA, BIO, and TMO together due to their shared focus on laboratory tools, diagnostics, and biopharma support services. These stocks appeal to those evaluating relative performance in a sector influenced by research funding cycles, technological innovation, and operational efficiency initiatives. This comparison highlights recent business developments, revenue trends, and positioning to assist in assessing diversification or tactical allocation opportunities within healthcare instrumentation and services.
AZTA Overview and Recent Performance
Azenta, Inc. provides sample management solutions and multiomics services primarily to the life sciences industry. In recent market activity, the company completed the sale of its B Medical Systems unit and received full early repayment of the associated $35 million vendor loan in early September 2026. Leadership transitioned in late August 2026 with the appointment of an interim chief executive following the prior CEO’s resignation. Third-quarter fiscal 2026 results showed reported revenue of $161 million, reflecting 12% year-over-year growth and 9% organic growth, supported by strength in recurring revenue lines. Guidance for the fourth quarter was reaffirmed, though adjusted EBITDA expectations incorporated one-time costs. The stock has traded in a range influenced by these corporate actions and broader sector dynamics.
BIO Overview and Recent Performance
Bio-Rad Laboratories, Inc. supplies life science research and clinical diagnostics products, including droplet digital PCR (ddPCR) platforms. Recent performance featured second-quarter 2026 revenue of approximately $651 million, essentially flat year over year, as growth in clinical diagnostics and digital PCR instruments offset softness in the life science academic segment. The company initiated a global restructuring plan expected to generate efficiency gains, with associated pre-tax charges in the $80–90 million range. Currency-neutral revenue guidance for the full year anticipates a range from a 3% decline to 0.5% growth. Participation in industry conferences has underscored ongoing product development and margin expansion targets. The shares have reflected mixed sentiment amid these operational adjustments.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. offers a broad portfolio of analytical instruments, reagents, consumables, and biopharma services. In recent market activity, second-quarter 2026 results delivered revenue of $11.99 billion, up 10% year over year with 5% organic growth—the strongest organic pace since 2021—prompting an upward revision to full-year guidance. The company completed the $1.1 billion sale of its microbiology business to a private equity firm in September 2026. Product launches, including expanded Orbitrap mass spectrometry platforms with AI-enabled features, have supported innovation momentum. Share repurchases and capital deployment continued alongside end-market strengthening in biopharma and research. The stock has demonstrated relative stability consistent with its scale and diversified exposure.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions, consistent performance metrics, and suitable risk profiles earn placement in this section. Available bots span diverse trading styles, strategies, timeframes, and ticker sets, with historical statistics that can include win rates, profit factors, and drawdown ranges varying by bot. This curated view provides traders with data-driven options for automated strategies. Review the full selection on the Trending AI Robots page for details on current offerings.
Head-to-Head Comparison
Business models differ in scale and focus: TMO operates as a diversified leader across instruments, diagnostics, and services with substantial recurring revenue; BIO emphasizes research tools and diagnostics with notable digital PCR exposure; and AZTA concentrates on specialized sample management and multiomics services. Growth drivers include TMO’s broad end-market recovery and portfolio optimization, BIO’s digital PCR momentum alongside restructuring, and AZTA’s post-divestiture focus amid leadership changes. Recent momentum favors TMO’s organic growth trajectory, while AZTA and BIO navigate internal transitions that introduce execution considerations. Risk factors encompass sector funding sensitivity for all, with AZTA carrying transition-related uncertainty, BIO facing academic demand softness, and TMO managing integration of acquisitions and divestitures. Valuation sensitivity appears higher for smaller-capitalization names, and market sentiment reflects greater stability for the largest player.
Tickeron AI Verdict
Based on observable factors such as trend consistency in organic growth, balance-sheet strengthening through divestitures, and relative positioning amid sector recovery, Tickeron’s AI would currently assign the highest probabilistic preference to TMO. Its demonstrated execution across multiple quarters and scale provide a buffer compared with the transition dynamics evident at AZTA and the margin-focused adjustments at BIO. This assessment remains probabilistic and subject to evolving market data rather than a definitive ranking.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AZTA | BIO | TMO | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 42 | 83 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 48 Fair valued | 88 Overvalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 72 | |
SMR RATING 1..100 | 92 | 87 | 60 | |
PRICE GROWTH RATING 1..100 | 36 | 41 | 28 | |
P/E GROWTH RATING 1..100 | 84 | 9 | 15 | |
SEASONALITY SCORE 1..100 | n/a | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (13) in the Medical Specialties industry is somewhat better than the same rating for AZTA (48) in the Electronic Production Equipment industry, and is significantly better than the same rating for BIO (88) in the Medical Specialties industry. This means that TMO's stock grew somewhat faster than AZTA’s and significantly faster than BIO’s over the last 12 months.
TMO's Profit vs Risk Rating (72) in the Medical Specialties industry is in the same range as AZTA (100) in the Electronic Production Equipment industry, and is in the same range as BIO (100) in the Medical Specialties industry. This means that TMO's stock grew similarly to AZTA’s and similarly to BIO’s over the last 12 months.
TMO's SMR Rating (60) in the Medical Specialties industry is in the same range as BIO (87) in the Medical Specialties industry, and is in the same range as AZTA (92) in the Electronic Production Equipment industry. This means that TMO's stock grew similarly to BIO’s and similarly to AZTA’s over the last 12 months.
TMO's Price Growth Rating (28) in the Medical Specialties industry is in the same range as AZTA (36) in the Electronic Production Equipment industry, and is in the same range as BIO (41) in the Medical Specialties industry. This means that TMO's stock grew similarly to AZTA’s and similarly to BIO’s over the last 12 months.
BIO's P/E Growth Rating (9) in the Medical Specialties industry is in the same range as TMO (15) in the Medical Specialties industry, and is significantly better than the same rating for AZTA (84) in the Electronic Production Equipment industry. This means that BIO's stock grew similarly to TMO’s and significantly faster than AZTA’s over the last 12 months.
| AZTA | BIO | TMO | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 68% | 1 day ago 82% | 1 day ago 47% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 77% | 1 day ago 55% |
| Momentum ODDS (%) | 1 day ago 77% | 1 day ago 64% | 1 day ago 59% |
| MACD ODDS (%) | 1 day ago 76% | 5 days ago 72% | 1 day ago 53% |
| TrendWeek ODDS (%) | 1 day ago 72% | 1 day ago 67% | 1 day ago 61% |
| TrendMonth ODDS (%) | 1 day ago 75% | 1 day ago 73% | 1 day ago 62% |
| Advances ODDS (%) | 1 day ago 72% | 1 day ago 66% | 1 day ago 63% |
| Declines ODDS (%) | 28 days ago 81% | 6 days ago 67% | 6 days ago 62% |
| BollingerBands ODDS (%) | 1 day ago 74% | 1 day ago 88% | 1 day ago 61% |
| Aroon ODDS (%) | 1 day ago 81% | 1 day ago 79% | 1 day ago 53% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZTA’s FA Score shows that 0 FA rating(s) are green while BIO’s FA Score has 1 green FA rating(s), and TMO’s FA Score reflects 3 green FA rating(s).
- AZTA’s FA Score: 0 green, 5 red.
- BIO’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZTA’s TA Score shows that 3 TA indicator(s) are bullish while BIO’s TA Score has 6 bullish TA indicator(s), and TMO’s TA Score reflects 3 bullish TA indicator(s).
- AZTA’s TA Score: 3 bullish, 5 bearish.
- BIO’s TA Score: 6 bullish, 3 bearish.
- TMO’s TA Score: 3 bullish, 5 bearish.
Price Growth
AZTA (@Pharmaceuticals: Other) experienced а +24.76% price change this week, while BIO (@Medical/Nursing Services) price change was +0.56% , and TMO (@Medical Specialties) price fluctuated -0.27% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.70%. For the same industry, the average monthly price growth was -3.92%, and the average quarterly price growth was +15.16%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.22%. For the same industry, the average monthly price growth was -4.30%, and the average quarterly price growth was -2.12%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.21%. For the same industry, the average monthly price growth was +5.94%, and the average quarterly price growth was +49.24%.
Reported Earning Dates
AZTA is expected to report earnings on Nov 17, 2026.
BIO is expected to report earnings on Oct 22, 2026.
TMO is expected to report earnings on Oct 21, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-1.70% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-0.22% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+0.21% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
AZTA and
Correlation & Price change
A.I.dvisor indicates that over the last year, AZTA has been loosely correlated with IQV. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if AZTA jumps, then IQV could also see price increases.
| Ticker / NAME | Correlation To AZTA | 1D Price Change % | ||
|---|---|---|---|---|
| AZTA | 100% | +10.27% | ||
| IQV - AZTA | 60% Loosely correlated | +3.05% | ||
| RVTY - AZTA | 59% Loosely correlated | +3.85% | ||
| A - AZTA | 59% Loosely correlated | +2.09% | ||
| MTD - AZTA | 59% Loosely correlated | +3.73% | ||
| BRKR - AZTA | 58% Loosely correlated | +0.98% | ||
More | ||||
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.
| Ticker / NAME | Correlation To TMO | 1D Price Change % | ||
|---|---|---|---|---|
| TMO | 100% | +3.35% | ||
| A - TMO | 74% Closely correlated | +2.09% | ||
| DHR - TMO | 73% Closely correlated | +3.34% | ||
| RVTY - TMO | 70% Closely correlated | +3.85% | ||
| IQV - TMO | 69% Closely correlated | +3.05% | ||
| BRKR - TMO | 67% Closely correlated | +0.98% | ||
More | ||||